KRAS and LBP1B mutations were significantly associated with tumor size, and patients with KRAS or LBP1B mutations had significantly larger tumor diameters as compared to patients with wild-type (median: 3.1 vs. 1.8 cm, p = 0.025; median:4.0 vs 2.0 cm, p = 0.013, respectively Figures 4B, C, and Table 5). Here, KRAS is linked to neoplasm.